Congrats, Romain and team!

Appearing soon in RPTH

Enoxaparin vs Tinzaparin or Dalteparin in cancer patients with VTE The #RIETEregistry experience appearing soon in RPTH

Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions | @jaccjournals.bsky.social www.jacc.org/doi/10.1016/...

Find it here: www.nature.com/articles/s41...

Identifying PE patients at increased risk for CTEPH A new #RIETEregistry study Thanks, Stephan and team

The VTE-PREDICT SCORE, externally validated using data from the #RIETEregistry Congratulations, Tim and team!

Impact of cancer site on outcomes in patients with acute VTE The #RIETEregistry experience

In patients with cancer-associated VTE, 90-day outcomes largely vary according to cancer sites Another #RIETEregistry study appearing soon in JACC Advances

Your 5 minute read for today 🤗 @mmonrealriete.bsky.social pubmed.ncbi.nlm.nih.gov/28120516/

Prognostic value of baseline PaCO2 levels on outcome in acute pulmonary embolism A new #RIETEregistry study appearing soon in Arch Bronconeumol

Interesting data on influence of race from the RIETE registry. After correction for treatment etc, these differences did not show in multi-variate analysis. #ISTH2025

Must do better for #PE risk stratification. In an @escardio.bsky.social #EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great leadership by #DavidJimenez @mmonrealriete.bsky.social #RIETE! 👇: tinyurl.com/trpmzbrd

VTE patients with low LDL-cholesterol levels are at increased risk for major bleeding during anticoagulation, particularly hematoma Another study from the #RIETEregistry Congratulations, Carmine and team!

Our manuscript on the impact of hemoglobin values at baseline and clinical outcomes in patients with acute venous thromboembolism has been accepted for publication in the Am J Hematol Congratulations, RIETE team!

Obese patients with acute PE have a lower mortality rate Find it here: www.rpthjournal.org/action/showP...

@luciaordieres.bsky.social @mmonrealriete.bsky.social #VTE #thrombosis #VTESky #IMSky #HemeSky

Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients www.nejm.org/doi/full/10....

@acc25.bsky.social Isabelle Mahe presents API-CAT Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!

NEJM Editorial Fellow Harleen Marwah, MD, summarizes the API-CAT trial. Read the full trial results: nej.md/41YkRZK #ACC25 #MedSky #CardioSky @accintouch.bsky.social

Obesity and early mortality in acute PE

PE patients with concomitant UEDVT are at a higher risk to die or to bleed within 90 days compared to those with concomitant LEDVT

A multimarker calculator of short-term outcomes in acute PE, accepted for publication in Eur Heart J Congratulations, David and team!

Should we treat similarly PE in patients with concomitant arm DVT than in those with concomitant lower-limb DVT? Sure??